Probiotic‐Enhanced Porous Bio‐Hybrids with Inflammatory Targeting, ROS Scavenging, and Long‐Term Drug Release for Ulcerative Colitis Treatment
Advanced Science · 2025
DOI: 10.1002/advs.202504802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Luna Quan und 7 weiteren Autor:innen. Beteiligte Einrichtung: PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou, 510006, P. R. China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Probiotics, Reactive Oxygen Species. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Major Project of Basic and Applied Basic Research.
Abstract (Originalsprache)
Functional porous materials hold significant promise for biomedical applications owing to their high surface area and customizable pore architectures. However, the complex gastrointestinal environment poses considerable challenges for conventional nanomaterials in achieving targeted accumulation and controlled drug release. Herein, a kind of novel probiotic‐enhanced porous bio‐hybrids (E‐ x PAM@ASA) is designed via bio‐hybridization of 5‐aminosalicylic acid‐loaded hairy microporous nanospheres ( x PAM@ASA) with probiotic Escherichia coli Nissle 1917. Benefiting from the intrinsic inflammatory‐targeting capability of EcN, the E‐ x PAM@ASA can accumulate in the inflammatory sites of the intestine. The unique porous architecture of x PAM@ASA not only facilitates high drug loading and long‐term release but also provides abundant adsorption sites for effective reactive oxygen species scavenging. In a dextran sulfate sodium‐induced ulcerative colitis murine model, E‐ x PAM@ASA demonstrate superior therapeutic outcomes, including mucosal repair, inflammation alleviation, and microbiota regulation. These findings highlight the potential of the multifunctional nanocomposite as a precise therapeutic platform for the treatment of intestinal inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou, 510006, P. R. China.
- Colorectal Surgery Unit III, Guangdong Institute of Gastroenterology, Biomedical Innovation Center, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen…
- The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, P. R. China.
ORCID-Profile: Bingna Zheng, Dingcai Wu, Rongkang Huang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangdong Major Project of Basic and Applied Basic Research
- Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- Shenzhen Science and Technology Program
- Guangdong Basic Research Center of Excellence for Functional Molecular Engineering
- National Key Clinical Discipline
Zitieren
APA
Quan, L., Ouyang, Y., Liang, W., Chen, Z., Miao, D., Zheng, B., Wu, D., & Huang, R. (2025). Probiotic‐Enhanced Porous Bio‐Hybrids with Inflammatory Targeting, ROS Scavenging, and Long‐Term Drug Release for Ulcerative Colitis Treatment. Advanced Science. https://doi.org/10.1002/advs.202504802
Vancouver
Quan L, Ouyang Y, Liang W, Chen Z, Miao D, Zheng B, et al. Probiotic‐Enhanced Porous Bio‐Hybrids with Inflammatory Targeting, ROS Scavenging, and Long‐Term Drug Release for Ulcerative Colitis Treatment. Advanced Science. 2025. doi:10.1002/advs.202504802
BibTeX
@article{Quan2025,
author = {Quan, Luna and Ouyang, Yang and Liang, Weiwen and Chen, Zixin and Miao, Dongtian and Zheng, Bingna and Wu, Dingcai and Huang, Rongkang},
title = {Probiotic‐Enhanced Porous Bio‐Hybrids with Inflammatory Targeting, ROS Scavenging, and Long‐Term Drug Release for Ulcerative Colitis Treatment},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504802}
}
EUVIMED